The 129 references in paper A. Smirnov V., V. Dobrobravov A., I. Kayukov G., A. Kucher G., F. Tugusheva A., I. Trofimenko I., I. Panina Yu., А. Смирнов В., В. Добронравов А., И. Каюков Г., А. Кучер Г., Ф. Тугушева А., И. Трофименко И., И. Панина Ю. (2008) “РЕКОМЕНДАЦИИ НАУЧНО-ИССЛЕДОВАТЕЛЬСКОГО ИНСТИТУТА НЕФРОЛОГИИ САНКТ-ПЕТЕРБУРГСКОГО ГОСУДАРСТВЕННОГО МЕДИЦИНСКОГО УНИВЕРСИТЕТА им. акад. И.П. ПАВЛОВА: ОПРЕДЕЛЕНИЕ, КЛАССИФИКАЦИЯ, ДИАГНОСТИКА И ОСНОВНЫЕ НАПРАВЛЕНИЯ ПРОФИЛАКТИКИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК У ВЗРОСЛЫХ // RECOMMENDATIONS OF THE RESEARCH INSTITUTE OF NEPHROLOGY OF ST.PETERSBURG MEDICAL UNIVERSITY NAMED AFTER I.P.PAVLOV: DEFINITION, CLASSIFICATION, DIAGNOSTICS AND MAIN TRENDS OF PROPHYLACTICS OF CHRONIC KIDNEY DISEASE IN ADULTS” / spz:neicon:nefr:y:2008:i:2:p:75-93

1
Смирнов АВ, Есаян АМ, Каюков ИГ Хроническая бо­ лезнь почек: на пути к единству представлений. Нефроло­ гия 2002; 6(4): 11-17
(check this in PDF content)
2
Смирнов АВ, Каюков ИГ, Есаян АМ и др. Превентив­ ный подход в современной нефрологии. Нефрология 2004; 8(3): 7-14
(check this in PDF content)
3
National Kidney Foundation KD: Clinical practice guidelines for chronic Kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 2002; 39 [Suppl 1]: S1-S266
(check this in PDF content)
4
European Best Practice Guidelines, Expert Group on Hemodialysis, European Renal Association. Section I. Measurement of renal function, when to refer and when to start dialysis. Nephrol Dial Transplant 2002; 17 [suppl 7]: 7-15
(check this in PDF content)
5
Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67(6): 2089-20100
(check this in PDF content)
6
Majunath G, Tighionart H, Ibrahim H et al. Level of kidney function as a risk factors for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47- 55
(check this in PDF content)
7
Henry RM, Kostense PJ, Bos G et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 2002; 62: 1402-1407
(check this in PDF content)
8
Nitsch D, Dietrich DF, von Eckardstein A et al. Prevalence of renal impairment and its association with cardiovascular risk factors in a general population: results of the Swiss SAPALDIA study. Nephrol Dial Transplant 2006; 21(4): 935-944
(check this in PDF content)
9
Segura J, Campo C, Ruilope LM. Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. Kidney Int 2004; [Suppl 92]:S45-9.2004
(check this in PDF content)
10
Mann JFE. Cardiovascular risk in patients with mild renal insufficiency: implication for the use of ACE inhibitors. La Presse Medicale 2005; 34(18): 1303-1308
(check this in PDF content)
11
Myllymaki J, Syrjanen J, Helin H et al.Vascular diseases and their risk factors in IgA nephropathy. Nephrol Dial Transplant 2006; 21(7):1876-1882
(check this in PDF content)
12
Смирнов АВ, Добронравов ВА, Каюков ИГ Кардио­ ренальный континуум: патогенетические основы превентив­ ной нефрологии. Нефрология 2005; 9(3): 7-15
(check this in PDF content)
13
Смирнов АВ, Добронравов ВА, Каюков ИГ и др. Эпи­ демиология и социально-экономические аспекты хроничес­ кой болезни почек. Нефрология 2006; 10(1): 7-13
(check this in PDF content)
14
Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351(13):1296-305
(check this in PDF content)
15
Glynn LG, Reddan D, Newell J et al. Chronic kidney disease and mortality and morbidity among patients with established cardiovascular disease: a West of Ireland community-based cohort study. Nephrol Dial Transplant 2007; 22(9): 2586-2594
(check this in PDF content)
16
Смирнов АВ, Добронравов ВА, Каюков ИГ, Есаян АМ. Хроническая болезнь почек: дальнейшее развитие кон­ цепции и классификации. Нефрология 2007; 11(4): 7-17
(check this in PDF content)
17
Stuveling EM, Bakker SJ, Hilige HX et al. Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol Dial Transplant 2005; 20: 497-508
(check this in PDF content)
18
Смирнов АВ, Добронравов ВА, Бодур-Ооржак АШ и др. Эпидемиология и факторы риска хронических болез­ ней почек: региональный уровень общей проблемы. Тер арх 2005; 77(6): 20-27
(check this in PDF content)
19
Halimi JM, Forhan A, Balkan B et al. Ig microalbuminuria an integrated risk marker for cardiovascular disease and insulin resistance in both men and women? J Cardiovasc Risk 2001; 8: 139-146
(check this in PDF content)
20
Orth SR. Smoking and the kidney. J Am Soc Nephrol 2002; 13: 1663-1672
(check this in PDF content)
21
Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S et al. Urinary albumin excretion: an independent predictor of ischemic heart disease. Thromb Vasc Biol 1999;19:1992-1997
(check this in PDF content)
22
Schmieder RE, Schrader J, Zidek W et al. Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol 2007; 96(5): 247-257
(check this in PDF content)
23
Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension 2005; 46(1): 33-37
(check this in PDF content)
24
Brantsma AH, Bakker SJ, Hillege HL et al. Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 2005; 28(10): 2525-2530
(check this in PDF content)
25
Forman JP, Brenner BM. «Hypertension» and «microalbuminuria»: The bell tolls for thee. Kidney Int 2006; 69: 22-28
(check this in PDF content)
26
Saweirs WWM, Goddard J. What are the best treatment for early chronic disease. Nephrol Dial Transplant 2007; 22 [Suppl 9]: ix31-ix39
(check this in PDF content)
27
Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51: 1908-1919
(check this in PDF content)
28
Remuzzi G, Ruggenenti, P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51: 2-15
(check this in PDF content)
29
Rossing P, Hommel E, Smidt U, Parving H. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994; 37: 511-516
(check this in PDF content)
30
Locatelli F, Del Vecchio L, D’Amico M, Andrulli S. Is it the agent or the blood pressure level that matters for renal protection in chronic nephropathies? J Am Soc Nephrol 2002; 13[Suppl 3]: S196-S201
(check this in PDF content)
31
Mann JF, Gerstein HC, Yi QL et al. HOPE Investigators: Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: Results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis 2003; 42: 936-942
(check this in PDF content)
32
Verhave JC, Hillege HL, Burgerhof JG, Gansevoort RT, de Zeeuw D, de Jong PE; PREVEND Study Group. The association between atherosclerotic risk factors and renal function in the general population. Kidney Int 2005; 67: 1967-1973
(check this in PDF content)
33
Lewis E, Hunsicker L, Clarke W et al. Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
(check this in PDF content)
34
Brenner B, Cooper M, de Zeeuw D et al. RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
(check this in PDF content)
35
Stevens LA, Greene T, Levey AS. Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol 2006; 1(4): 874-884
(check this in PDF content)
36
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16(1): 31-41
(check this in PDF content)
37
Levey AS, Bosch JP, Lewis JB. A more accurate method to estimate glomerular filtration rate from serum creatinine; a new prediction equation. Ann Intern Med 1999;130(8): 461-470
(check this in PDF content)
38
Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: A0828
(check this in PDF content)
39
Rodger RSC, Williams B. Consensus conference on early chronic kidney disease. Foreword. Nephrol Dial Transplant 2007; 22 [suppl 9]: ix:1
(check this in PDF content)
40
Мухин НА, Балкаров ИМ, Моисеев ВС и др. Хрони­ ческие прогрессирующие нефропатии и образ жизни со­ временного человека. Тер арх 2004; 76(9): 5-10
(check this in PDF content)
41
Chi-Yuan Hsu, Lin F, Vittinghoff E, Shlipac MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United State. J Am Soc Nephrol 2003; 14: 2902-2907
(check this in PDF content)
42
McClellan WM, Flanders WD. Risk factors for progressive chronic kidney disease. J Am Soc Nephrol 2003; 14: S65-S70
(check this in PDF content)
43
Мухин НА, Моисеев ВС, Кобалава ЖД и др. Кардиоре­ нальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер арх 2004; (6):39-46
(check this in PDF content)
44
Есаян АМ. Тканевая ренин-ангиотензиновая систе­ ма почки. Новая стратегия нефропротекции. Нефрология 2002; 6(3): 8-16
(check this in PDF content)
45
Добронравов ВА. Эпидемиология диабетической нефропатии: общие и региональные проблемы. Нефроло­ гия 2002; 6(1):16-22
(check this in PDF content)
46
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14):977-986
(check this in PDF content)
47
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352 (9131): 837-853
(check this in PDF content)
48
Ohkubo Y Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28(2): 103-117
(check this in PDF content)
49
Perera GA. Hypertensive vascular disease: description and natural history. J Chron Dis 1955; 1: 33-42
(check this in PDF content)
50
Ruelope ZM, Salvetti A, Jamerson K et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12: 218-225
(check this in PDF content)
51
Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomized to double-blind treatment with long- acting calcium- channel blocker or diuretic in International Nifidipine GITS study: Intervention as a goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356(9228): 366-372
(check this in PDF content)
52
Haroun NK, Jaar BG, Hoffman SC et al. Risk factors for chronic Kidney disease: a prospective study of 23.534 men and women in Washington Country, Maryland. J Am Soc Nephrol 2003; 14: 2934- 2941
(check this in PDF content)
53
United States Renal Date System. Annual date report, 2001
(check this in PDF content)
54
United States Renal Data System. Annual date report, 2002
(check this in PDF content)
55
Fried ZF, Orchard TJ, Kasiske BZ. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-269
(check this in PDF content)
56
Schaeffner ES, Kurth T, Curhan GC et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 2084-2091
(check this in PDF content)
57
Muntner P, Coresh J, Smith JC et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58: 293-301
(check this in PDF content)
58
Chen J, Munter P, Hamm LZ et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004; 140: 167-174
(check this in PDF content)
59
Tanaka H, Shiohira Y Uezu Y et al. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 2006; 69(2): 369-374
(check this in PDF content)
60
Hsu CY McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006 3;144(1): 21-28
(check this in PDF content)
61
Krikken JA, Lely AT, Bakker SJ, Navis G. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int 2007; 71(3): 260-265
(check this in PDF content)
62
Тугушева ФА, Зубина ИМ, Митрофанова ОВ. Окси- дативный стресс и хроническая болезнь почек. Нефроло­ гия 2007; 11 (3): 29-34
(check this in PDF content)
63
Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol 2004; 24(5): 469-473
(check this in PDF content)
64
Zalba G, Fortum A, Diez J. Oxidative stress and atherosclerosis in early chronic kidney disease. Nephrol Dial Transplant 2006; 21: 2686-2690
(check this in PDF content)
65
Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 23 342(12): 836-843
(check this in PDF content)
66
Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101(15):1767-1772
(check this in PDF content)
67
Pai JK, Pischon T, Ma J et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351(25):2599-2610; 60; 61
(check this in PDF content)
68
Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998; 54(2):627-636
(check this in PDF content)
69
Pereira BJ, Shapiro L, King AJ et al. Plasma levels of IL- 1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994; 45(3):890-896
(check this in PDF content)
70
Bassuk SS, Rifai N, Ridker PM. High-sensitivity C- reactive protein: clinical importance. Curr Probl Cardiol 2004; 29: 439-493
(check this in PDF content)
71
Keller CR, Odden MC, Fried LF et al. Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study. Kidney Int 2007; 71(3): 239-244
(check this in PDF content)
72
Anavekar NS, Pfeffer MA. Cardiovascular risk in chronic kidney disease. Kidney Int 2004; 66 [Suppl 92]: S11- S15
(check this in PDF content)
73
Zoccali C. Biomarkers in chronic kidney disease: utility and issues towards better understanding. Curr Opin Nephrol Hypertens 2005;14 (6):532-537
(check this in PDF content)
74
Annuk M, Soveri I, Zilmer M et al. Endothelial function, CRP and oxidative stress in chronic kidney disease. J Nephrol 2005; 18(6):721-726
(check this in PDF content)
75
Romao JE Jr, Haiashi AR, Elias RM et al. Positive acute- phase inflammatory markers in different stages of chronic kidney disease. Am J Nephrol 2006; 26(1): 59-66
(check this in PDF content)
76
Yoon JW, Pahl MV, Vaziri ND. Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal disease. Kidney Int 2007; 71(2):167-172
(check this in PDF content)
77
H ^l WH, Cohen JJ, Harrington JT et al. Atherosclerosis and uremic retention solutes. Kidney Int 2004; 66(4):1719-1731
(check this in PDF content)
78
Locatelli F, Pozzoni P, Del Vecchio L. Epidemiology of chronic kidney disease in Italy: Possible therapeutical approaches. J Nephrol 2003; 16: 1-10
(check this in PDF content)
79
Muntner P, He J, Astor BC et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 2005;16:529-538
(check this in PDF content)
80
Silverberg DS, Wexler D, Iaina A.The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron? J Nephrol 2004;17(6):749-761
(check this in PDF content)
81
Шутов АМ, Саенко ЮВ. Плеотропные кардиопротектив- ные эффекты эритропоэтина. Нефрология 2006; 10(4): 18-22
(check this in PDF content)
82
Pinto-Siersma SJ, Mulder J, Janssen WM et al. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 2000; 133:585-591
(check this in PDF content)
83
Warmoth L, Regalado MM, Simoni J et al. Cigarette smoking enhances increased urine albumin excretion as a risk factor for glomerular filtration rate decline in primary hypertension. Am J Med Sci 2005; 330(3): 111-119
(check this in PDF content)
84
Смирнов АВ, Седов ВМ, Лхаахуу Од-Эрдэнэ, Каю­ ков ИГ и др. Снижение скорости клубочковой фильтрации как независимый фактор риска сердечно-сосудистой бо­ лезни. Нефрология 2006; 10(4): 7-17
(check this in PDF content)
85
Кучер АГ, Каюков ИГ, Есаян АМ, Ермаков ЮА. Влия­ ние количества и качества белка в рационе на деятельность почек. Нефрология 2004; 8(2): 14-34
(check this in PDF content)
86
Кучер АГ, Каюков ИГ, Григорьева НД, Васильев АН. Лечебное питание на различных стадиях хронической бо­ лезни почек. Нефрология и диализ 2007
(check this in PDF content)
87
Uribarri J, Tuttle KR. Advanced glycation end products and nephrotoxicity of high-protein diets. Clin J Am Soc Nephrol 2006 1(6):1293-1299
(check this in PDF content)
88
Wesson DE, Nathan T, Rose T, Simoni J, Tran RM. Dietary protein induces endothelin-mediated kidney injury through enhanced intrinsic acid production. Kidney Int 2007 71(3):210-217
(check this in PDF content)
89
Lentine K, Wrone EM. New insights into protein intake and progression of renal disease. Curr Opin Nephrol Hypertens 2004; 13(3): 333-336
(check this in PDF content)
90
Pecoits-Filho R. Dietary protein intake and kidney disease in Western diet. Contrib Nephrol 2007;155:102-112
(check this in PDF content)
91
Sacks FM, Lichtenstein A, Van Horn L et al. Soy protein, isoflavones, and cardiovascular health: a summary of a statement for professionals from the american heart association nutrition committee. Arterioscler Thromb Vasc Biol 2006; 26(8):1689-1692
(check this in PDF content)
92
Ritz E. Salt-friend or foe? Nephrol Dial Transplant 2006; 21(8): 2052-2056
(check this in PDF content)
93
Ritz E, Dikow R, Morath C, Schwenger V. Salt-a potential ‘uremic toxin’? Blood Purif 2006; 24(1): 63-66
(check this in PDF content)
94
Burnier M, Phan O, Wang Q. High salt intake: a cause of blood pressure-independent left ventricular hypertrophy? Nephrol Dial Transplant 2007; 22(9): 2426-2429
(check this in PDF content)
95
Goodman WG, London G, Amann K et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004; 43(3): 572-579
(check this in PDF content)
96
Shoji T, Shinohara K, Kimoto E et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19(1):179-184
(check this in PDF content)
97
Xiang W, Kong J, Chen S et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288(1):E125-132
(check this in PDF content)
98
Nath KA, Hostetter MK, Hostetter TH. Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 1985; 76(2):667-675
(check this in PDF content)
99
Tang S, Sheerin NS, Zhou W, Brown Z, Sacks SH. Apical proteins stimulate complement synthesis by cultured human proximal tubular epithelial cells.J Am Soc Nephrol 1999; 10(1): 9-76
(check this in PDF content)
100
Disthabanchong S, Radinahamed P, Stitchantrakul W, Hongeng S, Rajatanavin R. Chronic metabolic acidosis alters osteoblast differentiation from human mesenchymal stem cells. Kidney Int 2007; 71(3): 201-209
(check this in PDF content)
101
Каюков ИГ, Смирнов АВ, Добронравов ВА. Рентге­ ноконтрастная нефропатия. Нефрология 2007; 11(3): 93-101
(check this in PDF content)
102
Волгина ГВ. Контраст-индуцированная нефропа­ тия: патогенез, факторы риска, стратегия профилактики (часть I). Нефрология и диализ 2006; 8(1): 69-77
(check this in PDF content)
103
Волгина ГВ. Контраст-индуцированная нефропа­ тия: патогенез, факторы риска, стратегия профилактики (часть II). Нефрология и диализ 2006; 8(2): 176-183
(check this in PDF content)
104
Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 15; 123(10):754-762
(check this in PDF content)
105
Kidney Disease Outcome Quality Initiative. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1-S290
(check this in PDF content)
106
Joint Speciality Committee on Renal Medicine of the Royal College of Physicians and the Renal Association atRCoGP. Chronic Kidney Disease in adults: UK guidelines for management and referral. Royal College of Physicians, London: 2006
(check this in PDF content)
107
Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560-2572
(check this in PDF content)
108
Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG Thom S; British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18(3): 139-185
(check this in PDF content)
109
Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. Vasc Health Risk Manag 2007;3(6):783-795
(check this in PDF content)
110
Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995;155(10):1073-1080
(check this in PDF content)
111
Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366 (9502): 2026-2233
(check this in PDF content)
112
Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139(4): 244-252
(check this in PDF content)
113
He J, Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J 1999; 138(3 Pt 2): 211-219
(check this in PDF content)
114
Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123(10):754-762
(check this in PDF content)
115
MacKinnon M, Shurraw S, Akbari A et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48(1): 8-20
(check this in PDF content)
116
Klahr S, Levey AS, Beck GJ et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330(13):877- 884
(check this in PDF content)
117
Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 2002 Jul; 62(1):220-228
(check this in PDF content)
118
Meloni C, Morosetti M, Suraci C, Pennafina MG, Tozzo C, Taccone-Gallucci M, Casciani CU. Severe dietary protein restriction in overt diabetic nephropathy: benefits or risks? J Ren Nutr 2002;12(2): 96-101
(check this in PDF content)
119
Pijls LT, de Vries H, van Eijk JT, Donker AJ. Protein restriction, glomerular filtration rate and albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Eur J Clin Nutr 2002; 56(12):1200-1207
(check this in PDF content)
120
Meloni C, Tatangelo P, Cipriani S et al. Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure. J Ren Nutr 2004; 14(4):208-213
(check this in PDF content)
121
Mitch WE. Dietary therapy in CKD patients - the current status. Am J Nephrol 2005; 25[suppl.1]: 7-8
(check this in PDF content)
122
Prakash S, Pande DP, Sharma S et al. Randomized, double-blind, placebo-controlled trial to evaluate efficacy of ketodiet in predialytic chronic renal failure. Ren Nut 2004; 14(2): 89-96
(check this in PDF content)
123
Teschan PE, Beck GJ, Dwyer JT et al. Effect of a ketoacid-aminoacid-supplemented very low protein diet on the progression of advanced renal disease: a reanalysis of the MDRD feasibility study. Clin Nephrol 1998; 50(5):273-283
(check this in PDF content)
124
Macdougall IC, Temple RM, Kwan JT. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial. Nephrol Dial Transplant 2007; 22(3):784-93
(check this in PDF content)
125
Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355(20): 2071-2084
(check this in PDF content)
126
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355(20): 2085-2098
(check this in PDF content)
127
Национальные Рекомендации по лечению анемии. М., 2007
(check this in PDF content)
128
Смирнов АВ. Дислипопротеидемии и проблемы нефропротекции. Нефрология 2002; 6(2): 8-14
(check this in PDF content)
129
Joint Speciality Committee on Renal Medicine of the Royal College of Physicians and the Renal Association atRCoGP. Chronic Kidney Disease in adults: UK guidelines for identification, management and referral. Royal College of Physicians, London: 2006
(check this in PDF content)